Olema Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the discovery development and commercialization of next generation targeted therapies for breast cancer and beyond. The company leverages its deep understanding of endocrine driven cancers nuclear receptors and mechanisms of acquired resistance to build a pipeline of novel small molecule therapeutics. Its lead product candidate palazestrant is an oral available small molecule that functions as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader. Olema is advancing palazestrant through late stage clinical development both as a monotherapy and in combination with other targeted agents. A second product candidate OP-3136 targets the epigenetic enzyme KAT6 and is currently in early phase clinical testing. The company owns worldwide development and commercialization rights to both candidates.

Olema Pharmaceuticals, Inc. does not yet generate revenue from product sales because none of its candidates have received marketing approval. The company's current revenue streams consist of upfront license fees milestone payments and research funding obtained through collaboration agreements with pharmaceutical partners. For example Olema has received an upfront payment and milestone payments from its licensing agreement with Aurigene Oncology for the KAT6 inhibitor program. Additionally the company benefits from clinical trial collaborations with Novartis and Pfizer which provide investigational drug supply at no cost and may trigger further milestone payments upon achievement of predefined development goals. Olema also pursues non dilutive financing through private placements and public offerings to support its research and development activities. Upon eventual regulatory approval and commercial launch of palazestrant or OP-3136 the company expects to generate product sales revenue from hospitals clinics and outpatient treatment centers.

Olema Pharmaceuticals, Inc. positions itself as an innovator in the endocrine therapy space for estrogen receptor positive breast cancer. The company differentiates its lead candidate palazestrant by combining complete estrogen receptor antagonism with potent receptor degradation in an oral formulation a profile that addresses limitations of existing therapies such as fulvestrant aromatase inhibitors and tamoxifen. Competitors in the estrogen receptor targeted arena include AstraZeneca with its drug camizestrant Roche with giredestrant Eli Lilly with imlunestrant Arvinas in partnership with Pfizer with vepdegestrant and Stemline Therapeutics with elacestrant. For its KAT6 program Olema faces competition from Pfizer's investigational KAT6 inhibitor Stemline Therapeutics MEN2312 and BeOne Medicines investigational KAT6 inhibitor. Olema's competitive advantages stem from its deep scientific expertise in nuclear receptor biology its ability to generate oral small molecules with favorable pharmacokinetics and its strategy of retaining full worldwide development and commercialization rights to its product candidates. The company also leverages strategic collaborations with major pharmaceutical firms to access complementary agents and share development costs while maintaining control over its intellectual property.

Olema Pharmaceuticals, Inc. serves patients with estrogen receptor positive breast cancer and other solid tumor indications through its therapeutic candidates. The company's primary customers are hospitals oncology clinics and outpatient treatment centers that would administer its approved drugs to eligible patients. In addition Olema works closely with pharmaceutical partners such as Novartis Pharma AG Pfizer Inc. and Aurigene Oncology to conduct clinical trials and develop combination regimens. These collaborations provide access to investigational agents and expertise while allowing Olema to retain rights to its own molecules. The company also engages with academic research institutions and patient advocacy groups to gather clinical insights and support trial enrollment.